PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Status:
Completed

Trial end date:
2017-07-28

Target enrollment:

Participant gender:

Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.

Phase 2

Glycotope GmbH